Table 1.
Publication type identified for the most commonly reported cytotoxic and non-cytotoxic antineoplastics (25 reports or more).
| DRUG | Total | Analytical method development and validation | Clinical trials and primary studies | Modelling and simulation | Reviews and perspectives |
|---|---|---|---|---|---|
| Cytotoxic antineoplastics | |||||
| methotrexate | 78 | 35 (44.9%) | 14 (17.9%) | 10 (12.8%) | 19 (24.4%) |
| 5-fu/fluorouracil | 57 | 15 (26.3%) | 13 (22.8%) | 6 (10.5%) | 23 (40.4%) |
| carboplatin | 34 | 3 (8.8%) | 11 (32.4%) | 9 (26.5%) | 11 (32.4%) |
| paclitaxel | 25 | 10 (40%) | 4 (16%) | 3 (12%) | 8 (32%) |
| Cytotoxic antineoplastic classes | |||||
| platinum agents | 50 | 6 (12%) | 18 (36%) | 13 (26%) | 13 (26%) |
| taxanes | 32 | 12 (37.5%) | 7 (21.9%) | 3 (9.4%) | 10 (31.2%) |
| Non-cytotoxic antineoplastics | |||||
| tamoxifen | 30 | 7 (23.3%) | 11 (36.7%) | 3 (10%) | 9 (30%) |
| asparaginase | 25 | 3 (12%) | 12 (48%) | 1 (4%) | 9 (36%) |
| Kinase inhibitors | |||||
| all kinase inhibitors | 242* | 116 (47.2%) | 69 (28%) | 23 (9.3%) | 38 (15.4%) |
| imatinib | 117 | 47 (40.2%) | 26 (22.2%) | 11 (9.4%) | 33 (28.2%) |
| sunitinib | 50 | 16 (32%) | 16 (32%) | 5 (10%) | 13 (26%) |
| erlotinib | 35 | 19 (54.3%) | 6 (17.1%) | 4 (11.4%) | 6 (17.1%) |
| pazopanib | 34 | 14 (41.2%) | 11 (32.4%) | 3 (8.8%) | 6 (17.6%) |
| nilotinib | 33 | 25 (75.8%) | 3 (9.1%) | 0 (0%) | 5 (15.2%) |
| dasatinib | 31 | 22 (71%) | 4 (12.9%) | 0 (0%) | 5 (16.1%) |
| sorafenib | 25 | 16 (64%) | 2 (8%) | 1 (4%) | 6 (24%) |
| Antineoplastic monoclonal antibodies | |||||
| all monoclonal antibodies | 39 | 16 (41%) | 7 (17.9%) | 2 (5.1%) | 14 (35.9%) |
*Four reports were in two of the categories indicated.